Promente Clinical Research Center
COMP 006 clinical trial
Active — not recruiting. Sponsored by COMPASS Pathways.
Study purpose
COMP 006 is a clinical research study of an investigational approach related to symptoms of treatment-resistant depression, using COMP360, a synthetic form of psilocybin, together with psychological support.
What is COMP360?
COMP360 is a synthetic form of psilocybin. The study evaluates safety and clinical outcomes in people whose depression has not responded sufficiently to standard antidepressant treatment.
Who was the study designed for?
- Adults with diagnosed treatment-resistant depression.
- People for whom at least two antidepressant medicines have not provided sufficient improvement.
- Eligibility was assessed by the study physician according to the protocol.
Recruitment for COMP 006 is closed
The official registry lists COMP 006 as active, not recruiting. See studies currently accepting inquiries.